Biofrontera Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$4.4M
Doctors Paid
8,848
Transactions
28,890
2024 Total
$633,336
Payment Breakdown by Category
Research$2.8M (63.9%)
Food & Beverage$609,615 (13.9%)
Consulting$417,270 (9.5%)
Travel$30,035 (0.7%)
Royalty/License$22,500 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.8M | 251 | 63.9% |
| Food and Beverage | $609,615 | 27,700 | 13.9% |
| Consulting Fee | $417,270 | 172 | 9.5% |
| Honoraria | $216,396 | 582 | 4.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $196,527 | 93 | 4.5% |
| Debt forgiveness | $79,582 | 9 | 1.8% |
| Travel and Lodging | $30,035 | 74 | 0.7% |
| Royalty or License | $22,500 | 4 | 0.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $8,155 | 4 | 0.2% |
| Grant | $2,500 | 1 | 0.1% |
Payments by Type
Research
$2.8M
251 transactions
General
$1.6M
28,639 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A randomized, double blind, vehicle-co ntrolled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT). | $737,276 | 15 | 81 |
| A randomized, double blind, vehicle-controlled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT). | $384,235 | 0 | 29 |
| A randomized, double blind, vehicle-controlled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz ) and BF-RhodoLED in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT). | $326,611 | 0 | 44 |
| A two-arm parallel, open-label phase I study to evaluate the pharmacokinetics of 5-aminolevulinic acid and protoporphyrin IX in human plasma under maximal use conditions after topical application of 3 tubes ofBF-200 ALA10% gel for photodynamic therapy (PDT)in subjects suffering from actinic keratosis | $199,123 | 0 | 6 |
| CCCR 02-2017 | $180,000 | 0 | 1 |
| A Randomized, Double-Blind, Parallel Group Comparison Study to Determine teh safety and effiacy of Ameluz | $129,290 | 1 | 1 |
| ALA-AK-CT019 | $80,538 | 0 | 5 |
| Safety and Efficacy of Photodynamic Therapy with Aminolevulinic Acid 10% Topical Gel Activated by Red Light versus Aminolevulinic Acid 20% Topical Solution Activated by Blue Light for the Treatment of Actinic Keratosis on the Upper Extremities: A Blinded Randomized Study | $59,603 | 0 | 5 |
| Photodynamic Therapy with Ameluz and BF-RhodoLED lamp With and Without Topical Adapelene Gel 0.1% Pre-Treatment in the Treatment of Dorsal Hand/Forearm Actinic Keratosis | $45,700 | 1 | 5 |
| Short contact protocols to reduce pain during actinic keratosis treatment with ALA gel red light photodynamic therapy (PDT) | $40,946 | 0 | 2 |
| "Short contact protocols to reduce pain during actinic keratosis treatment with ALA gel red light photodynamic therapy (PDT)" | $38,446 | 0 | 1 |
| A Single Center, Retrospective, Observational, Descriptive Case Series on the Safety of Photodynamic Therapy with Ameluz (aminolevulinic acid hydrochloride) 10% Gel PDT for Adult Subjects with Actinic Keratosis | $38,020 | 1 | 2 |
| Retrospective descriptive study on PDT with Ameluz 10% | $31,000 | 1 | 1 |
| A Single Observational Study to Evaluate the Effectiveness and Safety of Cryotherapy in Combination with 10% ALA Gel Red Light PDT in the Treatment of Actinic Keratosis on the Full Face | $28,305 | 0 | 1 |
| Assessment of BF-RhodoLED Light Photodynamic Therapy with Intense Pulsed Light of 10% Aminolevulinic Acid Hydrochloride Gel for Sun-Damaged Decollete. | $28,000 | 1 | 2 |
| ALA-ACV-CT014 | $25,394 | 0 | 6 |
| AMELUZ PDT | $24,975 | 0 | 1 |
| Photodynamic Therapy for Squamous Cell Carcinoma In Situ on the trunk and extremities with ALA 10% Gel and Red light Illumination | $23,982 | 1 | 3 |
| Photodynamic Therapy for SCCis on the trunk and extremities with ALA 10% gel and red-light illumination | $21,181 | 0 | 1 |
| A non-randomized, open-label, multicenter study to evaluate the safety and tolerability of BF-200 ALA (Ameluz) in the expanded field-directed treatment of actinic keratosis on the face and scalp with photodynamic therapy (PDT) | $19,405 | 0 | 10 |
| PHOTODYNAMIC THERAPY FOR SQUAMOUS CELL CARCINOMA IN SITU ON THE EXTREMITIES WITH ALA AND RED LIGHT | $18,331 | 0 | 2 |
| ALA-AK-CT018 | $17,776 | 0 | 1 |
| MICRONEEDLING-ASSISTED DELIVERY OF AMELUZ FOR SHORT INCUBATION PHOTODYNAMIC THERAPY WITH BF-RHODOLED | $17,500 | 0 | 1 |
| An Investigator Initiated Study to Evaluate the Safety and Efficacy of Aminolevulinic Acid Hydrochloride Gel, 10% (Ameluz) with RhodoLED XL Red Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) | $17,379 | 0 | 1 |
| An Investigator Initiated Study to Evaluate the Safety and Efficacy of Aminolevulinic acid hydrochloride topical gel, 10% (Ameluz) with RhodoLED XL Red Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) | $17,379 | 0 | 1 |
| A randomized, double blind, vehicle-controlled, multicenter Phase II study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the treatment of moderate to severe Acne vulgaris in adults with photodynamic therapy (PDT). | $15,688 | 0 | 8 |
| A randomized, double-blind, vehicle-controlled, multicenter Phase III study to evaluate the safety, tolerability, and efficacy of BF-200 ALA (Ameluz) in the field-directed treatment of actinic keratosis on the extremities and neck/trunk with photodynamic therapy (PDT) using the BF-RhodoLED XL or BF-RhodoLED lamp | $11,719 | 0 | 1 |
| Safety and Efficacy of Photodynamic Therapy with Aminolevulinic Acid 10% Topical Gel Activated by Red Light Versus Aminolevulinic Acid 20% Topical Solution Activated by Blue Light for the Treatment of Actinic Keratosis on the Upper Extremities: A Blinded Randomized Study | $11,000 | 0 | 1 |
| microneedling assisted delivery of ameluz for short incubation | $10,500 | 1 | 1 |
| CTO14 | $10,000 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Mitchel Goldman, M.d, M.D | Procedural Dermatology | San Diego, CA | $10,826 | $0 |
| Dr. Edward Lain, M.d, M.D | Dermatology | Austin, TX | $9,006 | $0 |
| Brent Moody, Md, MD | MOHS-Micrographic Surgery | Nashville, TN | $8,617 | $0 |
| Carl Hanke, Md, MD | MOHS-Micrographic Surgery | Indianapolis, IN | $8,108 | $0 |
| Dr. Macrene Alexiades, Md Phd, MD PHD | Dermatology | New York, NY | $8,042 | $0 |
| Dr. Lawrence Schachner, Md, MD | Dermatology | Miami, FL | $7,538 | $0 |
| Mr. Rawn Bosley, M.d, M.D | MOHS-Micrographic Surgery | Grapevine, TX | $7,390 | $0 |
| Dr. Michael O'donoghue, M.d, M.D | Dermatology | Westchester, IL | $7,301 | $0 |
| Sadra Jazayeri, Md, MD | Dermatology | Phoenix, AZ | $6,818 | $0 |
| Dr. Ryan Freeland, Md, MD | Dermatology | Wyoming, MI | $6,634 | $0 |
| Leon Kircik, Md, MD | Dermatology | Lousiville, KY | $6,631 | $0 |
| Dr. Michael Gold, M.d, M.D | Specialist | Nashville, TN | $6,446 | $0 |
| Dr. Harold Farber, M.d,, M.D, | Dermatology | Philadelphia, PA | $6,076 | $0 |
| Dr. Brian Berman, M.d., Ph.d, M.D., PH.D | Dermatology | Aventura, FL | $5,969 | $0 |
| Mr. Robert Lieberman, M.d, M.D | Dermatology | Henderson, NV | $5,954 | $0 |
| Dr. Howard Rogers, Md, MD | Dermatology | Norwich, CT | $5,919 | $0 |
| Danielle Dehoratius, M.d, M.D | Dermatology | Bryn Mawr, PA | $5,852 | $0 |
| Dr. Kristen Aguirre, Md, MD | MOHS-Micrographic Surgery | Oceanside, CA | $5,326 | $0 |
| George Drew, Do, DO | Dermatology | Marion, OH | $5,277 | $0 |
| Alison Young, Md, MD | Dermatopathology | Seattle, WA | $5,102 | $0 |
| Dr. James Del Rosso, Do, DO | MOHS-Micrographic Surgery | Las Vegas, NV | $5,019 | $0 |
| Jeffrey Brackeen, M.d, M.D | MOHS-Micrographic Surgery | Lubbock, TX | $4,912 | $0 |
| Michael Chapman, M.d, M.D | Dermatology | Lebanon, NH | $4,885 | $0 |
| Dr. Maria Tsoukas, M.d., Ph.d, M.D., PH.D | Procedural Dermatology | Chicago, IL | $4,835 | $0 |
| Dr. Geeta Patel, D.o, D.O | Dermatology | Houston, TX | $4,835 | $0 |
Ad
Top Products
- AMELUZ $2.4M
- Ameluz $1.8M
Associated Products (2)
- AMELUZ $2.4M
- BF-RhodoLED $231,463
Payment Categories
- Food & Beverage $609,615
- Consulting $417,270
- Travel & Lodging $30,035
- Research $2.8M
- Royalties $22,500
About Biofrontera Inc.
Biofrontera Inc. has made $4.4M in payments to 8,848 healthcare providers, recorded across 28,890 transactions in the CMS Open Payments database. In 2024, the company paid $633,336. The top product by payment volume is AMELUZ ($2.4M).
Payments were distributed across 116 medical specialties. The top specialty by payment amount is Dermatology ($1.2M to 3,715 doctors).
Payment categories include: Food & Beverage ($609,615), Consulting ($417,270), Research ($2.8M), Travel & Lodging ($30,035), Royalties ($22,500).
Biofrontera Inc. is associated with 2 products in the CMS Open Payments database.